Jones Financial Companies Lllp boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by ...

Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...

Equities researchers at Zacks Research decreased their Q3 2026 earnings per share (EPS) estimates for shares of Vertex ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston, Massachusetts-based company engages in developing and ...

With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...